Table 2 |
||
|
Genes significantly upregulated or downregulated by hypoxia and/or dimethyloxalylglycine in human rheumatoid arthritis fibroblast-like synoviocytes |
||
|
Genes that change only in response to hypoxia |
Genes that change only in response to DMOG |
Genes that change in response to hypoxia and DMOG |
|
|
||
|
TGF-β1 (2*) |
NRP2 (-2*) |
VEGF (8*/31*) |
|
HPSE (-2*) |
ID3 (-3*) |
PLAU (-2*/-2*) |
|
FIGF (-2*) |
EFNB2 (5*) |
LEP (108***/85***) |
|
CXCL-5 (-2*) |
CCL2 (-4*) |
HIF1A (-2*/-2*) |
|
CCL-11 (-9*) |
HAND2 (-2*/-6*) |
|
|
EFNA3 (2*/9*) |
||
|
ANGPTL4 (12**/48**) |
||
|
|
||
|
Genes significantly upregulated or downregulated by a factor ≥2. Genes from Figure 1b,c that change following 24 hours of hypoxia and in response to stimulation with the hypoxia-inducible factor activator dimethyloxalylglycine (DMOG) in rheumatoid arthritis fibroblast-like synoviocytes from five and three patients, respectively. Data presented as mean fold-change. Genes that changed significantly (P < 0.05) by a factor ≥2-fold were analysed by paired Student's t test comparing ΔCt values: *P < 0.05, **P < 0.001, ***P < 0.001. ANGPTL, angiopoietin-like; EFNA3, ephrin A3;EFNB2, ephrin B2; FIGF, C-fos-induced growth factor (VEGF D); HAND2, Heart and neural crest derivatives expressed 2; HPSE, heparanase; ID3, inhibitor of DNA-binding 3, dominant negative helix-loop-helix protein; LEP, leptin; NRP2, neuropillin 2; PLAU, plasminogen activator urokinase; TGF, transforming growth factor; VEGF, vascular endothelial growth factor. |
||
|
Larsen et al. Arthritis Research & Therapy 2012 14:R180 doi:10.1186/ar3934 |
||
